Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.79 |
| ▸ | F2 | P00734 | 9/20 | 0.79 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.63 |
| ▸ | PROC | P04070 | 4/20 | 0.63 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.63 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.63 |
| ▸ | F9 | P00740 | 3/20 | 0.63 |
| ▸ | KLK1 | P06870 | 1/20 | 0.63 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.62 |
| ▸ | CFH | P08603 | 1/20 | 0.62 |
| ▸ | PLAU | P00749 | 1/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100150 | 0.94 | F10 (0.79) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176283 | 0.93 | F10 (0.80) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176284 | 0.90 | F10 (0.74) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176279 | 0.87 | F10 (0.71) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176262 | 0.87 | F10 (0.71) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176260 | 0.87 | F10 (0.70) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176273 | 0.87 | F10 (0.70) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176261 | 0.87 | F10 (0.70) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176239 | 0.87 | F10 (0.70) | F10F2PRSS1PROCPRSS2 | |
| SCHEMBL14176259 | 0.86 | F10 (0.69) | F10F2PRSS1PROCPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381732-B2 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381732-B2 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381732-B2 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1812403-A2 | PYRAZOLOBENZAMIDES AND DERIVATIVES AS FACTOR XA INHIBITORS | Brystol-Myers Squibb Company (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006047528-A2 | PYRAZOLOBENZAMIDES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089496-A1 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089496-A1 | Pyrazolobenzamides and derivatives as factor Xa inhibitors | F12, TFPI, PRSS1 | F10 50/4885F2 11/4885PRSS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.